

# KASHYAP TELE-MEDICINES LIMITED

CIN: L29110MH1995PLC085738

Regd. Off.: 2<sup>nd</sup> Floor, Pushpawati Building No. 2, Girgaon Road, Chandanwadi, Mumbai -02

Corp. Off. : UL/8, Upper Floor, Suryarath Complex, Panchwati 1<sup>st</sup> Lane Ambawadi,  
Ahmedabad, Gujarat-380006

Phone: +91-6359637788, Email: [investor.relations@kashyaptele-medicines.com](mailto:investor.relations@kashyaptele-medicines.com),

Website: [www.kashyaptele-medicines.com](http://www.kashyaptele-medicines.com)

Date: 09<sup>th</sup> February, 2022

To,  
BSE Limited  
Listing Department  
Phiroz Jeejeebhoy Tower,  
25<sup>th</sup> Floor, Dalal Street,  
Mumbai-400001

Scrip Code – 531960

Sub.: Submission of Unaudited Financial Results of the Company and Limited Review Report thereon as per regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the third quarter and nine months ended 31<sup>st</sup> December, 2021

Dear Sir/Madam,

With reference to aforementioned subject and in pursuance to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, kindly find enclosed herewith a copy of Unaudited Financial Results of the Company for the third quarter and nine months ended 31<sup>st</sup> December, 2021 prepared in accordance with Companies (Indian Accounting Standards) Rules, 2015 (IND-AS) alongwith the Limited Review Report as received by the Statutory Auditors thereupon as duly reviewed by the Audit Committee and subsequently approved by the Board of Directors of the Company at their respective meetings held on 09<sup>th</sup> February, 2022.


Further, pursuant to Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the said results shall be duly published in the required newspaper within prescribed timeframe and shall be uploaded on the website of the Company.

You are kindly requested to acknowledge and update the above disclosure into records.

Thanking you

Yours faithfully,

For, KASHYAP TELE-MEDICINES LIMITED

  
PARITOSH TRIVEDI  
COMPANY SECRETARY



Encl: As above



# SAREMAL & CO

## Chartered Accountants

CA Saremal Shah (Bcom, FCA); CA Pravin Lavana (Bcom, LLB, FCA)

**INDEPENDENT AUDITOR'S LIMITED REVIEW REPORT ON THE QUARTERLY UNAUDITED FINANCIAL RESULTS FOR THE THIRD QUARTER AND NINE MONTHS ENDED 31<sup>ST</sup> DECEMBER, 2021 OF THE COMPANY PURSUANT TO THE REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015, AS AMENDED**

To  
The Board of Directors,  
KASHYAP TELE-MEDICINES LIMITED  
AHMEDABAD

1. We have reviewed the accompanying statement of Un-audited Financial Results of M/S KASHYAP TELE-MEDICINES LIMITED (the Company) for the third quarter and nine months ended 31<sup>st</sup> December, 2021 being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 as amended (the 'Listing Regulations'), read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated 5<sup>th</sup> July, 2016, SEBI Circular No. CIR/CFD/CMD1/44/2019 dated 29<sup>th</sup> March, 2019 and SEBI Circular No. CIR/CFD/CMD1/80/2019 dated 19<sup>th</sup> July, 2019. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial Results based on our review.
2. We conducted our review in accordance with the Statement on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial Results are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Our Conclusion is not modified in respect of this matter.



FOR SAREMAL & CO.  
Chartered Accountants

PRAVIN LAVANA  
Partner

MEMBERSHIP NO.: 037180  
FIRM REGISTRATION NO.: 109281W  
UDIN No. : 22037180AAYVZE8337

Ahmedabad, February 09, 2022

# KASHYAP TELE-MEDICINES LIMITED

CIN: L29110MH1995PLC085738

Regd. Off.: 2nd Floor, Pushpawati Building No. 2, Girgaon Road, Chandanwadi, Mumbai -02  
 Corp. Off. : UL/8, Upper Floor, Suryarath Complex, Panchwati 1st Lane Ambawadi, Ahmedabad, Gujarat-380006  
 Phone: +91-6359637788, Email: investor.relations@kashyaptele-medicines.com  
 Website: www.kashyaptele-medicines.com

## STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER 2021 (As per Schedule III Companies Act, 2013 and IND-AS)

(Rs in Lakhs Except EPS)

S.No.	Particulars	Quarter Ended			Nine Months Ended		Year Ended
		31-12-2021	30-09-2021	31-12-2020	31-12-2021	31-12-2020	31-03-2021
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
I	Revenue from operations	5.80	4.75	4.80	15.55	14.79	18.54
II	Other Income	0.00	0.00	0.00	0.00	0.00	0.14
III	<b>Total Revenue ( I + II )</b>	<b>5.80</b>	<b>4.75</b>	<b>4.80</b>	<b>15.55</b>	<b>14.79</b>	<b>18.68</b>
IV	<b>Expenses</b>						
	(a) Cost of materials consumed	0.00	0.00	0.00	0.00	0.00	0.00
	(b) Purchases of stock-in-trade	0.00	0.00	0.00	0.00	0.00	0.00
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	0.00	0.00	0.00	0.00	0.00	0.00
	(d) Employee benefits expense	2.54	2.22	2.39	6.97	6.33	8.65
	(e) Finance Cost	0.00	0.00	0.00	0.00	0.00	0.00
	(f) Depreciation and amortisation expense	0.00	0.00	0.00	0.00	0.00	0.00
	(g) Other expenses	1.98	1.97	2.18	5.84	6.44	8.54
	<b>Total expenses</b>	<b>4.52</b>	<b>4.19</b>	<b>4.56</b>	<b>12.81</b>	<b>12.76</b>	<b>17.19</b>
V	<b>Profit before exceptional and extraordinary items and tax (III-IV)</b>	<b>1.28</b>	<b>0.56</b>	<b>0.24</b>	<b>2.74</b>	<b>2.03</b>	<b>1.49</b>
VI	Exceptional and Extraordinary Items	0.00	0.00	0.00	0.00	0.00	0.00
VII	<b>Profit Before Tax ( V- VI)</b>	<b>1.28</b>	<b>0.56</b>	<b>0.24</b>	<b>2.74</b>	<b>2.03</b>	<b>1.49</b>
VIII	Tax Expense :-						
	(a) Current Tax	0.30	0.12	0.10	0.63	0.51	0.39
	(b) Deferred Tax	0.00	0.00	0.00	0.00	0.00	0.00
	<b>Total Tax Expense</b>	<b>0.30</b>	<b>0.12</b>	<b>0.10</b>	<b>0.63</b>	<b>0.51</b>	<b>0.39</b>
IX	<b>Profit / (Loss) for the period from Continuing Operations (VII-VIII)</b>	<b>0.98</b>	<b>0.44</b>	<b>0.14</b>	<b>2.11</b>	<b>1.52</b>	<b>1.10</b>
X	Profit/(Loss) from Discontinuing Operations	0.00	0.00	0.00	0.00	0.00	0.00
XI	Tax expense of Discontinuing Operations	0.00	0.00	0.00	0.00	0.00	0.00
XII	Profit/(Loss) from Discontinuing Operations (after tax) (X-XI)	0.00	0.00	0.00	0.00	0.00	0.00
XIII	<b>Profit / (Loss) for the period (IX + XII )</b>	<b>0.98</b>	<b>0.44</b>	<b>0.14</b>	<b>2.11</b>	<b>1.52</b>	<b>1.10</b>
XIV	Share of Profit / (Loss) of Associates	N.A	N.A	N.A	N.A	N.A	N.A
XV	Minority Interest	N.A	N.A	N.A	N.A	N.A	N.A
XVI	<b>Profit / (Loss) after Taxes, minority interest and share of profit / (loss) of associates</b>	<b>0.98</b>	<b>0.44</b>	<b>0.14</b>	<b>2.11</b>	<b>1.52</b>	<b>1.10</b>
XVII	<b>Other Comprehensive Income</b>						
	A. Items that will be/will not be reclassified through profit and loss	0.00	0.00	0.00	0.00	0.00	0.00
	B. Income Tax Relating to Items that will be/will not be reclassified through profit and loss	0.00	0.00	0.00	0.00	0.00	0.00
XVIII	<b>Total comprehensive income for the period (XVI+XVII)</b>	<b>0.98</b>	<b>0.44</b>	<b>0.14</b>	<b>2.11</b>	<b>1.52</b>	<b>1.10</b>
XIX	Paid-up Equity Share Capital (Face Value of Rs. 1/- each)	477.22	477.22	477.22	477.22	477.22	477.22
XX	Earnings per equity Share: (not annualised)	0.002	0.001	0.000	0.004	0.003	0.002
	(a) Basic and Diluted EPS (XVI/XIX)						

### Notes:

- The above Unaudited Financial Results of the Company for the third quarter & nine months ended 31st December, 2021 have been reviewed by the Audit Committee and approved by the Board of Directors in the Meeting held on 09th February, 2022.
- The Company has adopted, Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 ('Ind As') from 1st April, 2017 and accordingly these financial results and all the periods presented have been prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 "Interim Financial Reporting" read with relevant rules issued thereunder and the other accounting principles generally accepted in India and discloses the information required to be disclosed in terms of Regulation 33 of the Securities and Exchange Board of India ( Listing Obligations and Disclosure Requirements) Regulation, 2015 ( as amended).
- The Statutory Auditors of the Company have carried out Limited Review of the above unaudited Financial Results for the third quarter and nine months ended on 31st December, 2021 in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015.
- Estimates of uncertainties relating to the global pandemic from COVID-19:  
The Company has considered the possible effects that may result from the pandemic relating to COVID-19 on the carrying amounts of receivables, revenues and intangible assets. In developing the assumptions relating to the possible future uncertainty in the global economic condition because of this pandemic, the Company as at the date of approval of these financial Results has used internal and external sources of informations, economic forecasts and consensus estimates from market sources on the expected future performance of the Company. The Company has performed sensitivity analysis on the estimates expects the carrying amount of these assets will be recovered.
- A Copy of the aforesaid financial results is also available on the website of BSE Limited (www.bseindia.com) and on the website of the Company (www.kashyaptele-medicines.com).
- The company is engaged in single segment therefore has only one reportable segment in accordance with Ind AS 108 'Operating Segments'.
- Figures pertaining to previous year/periods have been re-grouped and re-arranged wherever necessary.

Place : Ahmedabad  
 Date : 09th February, 2022



For, Kashyap Tele - Medicines Limited



Amit Agarwal  
 Managing Director  
 DIN: 00169061